Marianne Mertens - Profile and Investment Details

Investor Profile

Marianne Mertens is a Venture Capital, Private Equity Firm, Finance Operator, Investor based in Munich, Bavaria, Germany with a diverse investment portfolio that includes companies such as UiPath, Heliatek, import.io, invendo medical, Auron Therapeutics, Hintsa, ImevaX, Confo Therapeutics, Ztory, Rigontec, Atopix Therapeutics, immatics biotechnologies, GLO, NEUWAY Pharma, ImCheck Therapeutics, HAYA Therapeutics, Onfido, Themis Bioscience, Soundtrack Your Brand, Scripta Therapeutics, Zopa, AYOXXA, YPlan, AMBOSS, Cardior Pharmaceuticals, 4SC, coramaze technologies GmbHEdge Intelligence Software, SNIPR Biome - A CRISPR Company, Aeovian Pharmaceuticals, Blackbuck, Polares Medical, Wool and the Gang, Middle Peak Medical, UroMems, 4TEEN4 Pharmaceuticals, EGenesis, Carisma Therapeutics, Minervax, Definiens, Nosto, GTX medical, STipe Therapeutics, Workframe, Dalia Research, Quanta, Booster Therapeutics, SidekickHealth, Festicket, Therini Bio, Inc., Artfinder, Mapillary, Cleara Biotech, Orcan Energy, Jellynote, Dacuda, SNIPR Biome, Koa Health, SumAll, Cavendish Kinetics, FREE NOW, EndoStim, IconOVir Bio, SuperSonic Imagine, opvizor, PreOmics GmbH, Tricares, Adrenomed, IOmx Therapeutics, EyeEm, Tonsser, SIRS Therapeutics, Genticel, . Over time, Marianne Mertens has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Marianne Mertens is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Brain Health, Patient Care, Health Care, Drug Discovery, Genetics, Wellness, Women Founded, Immunotherapy, Fundraising, Healthcare Innovation, Life Science, Engineering, Banking, Venture Fundraising, Finance, Biotechnology, Drug Development, Electronic Health Records (EHR), Genomics, Productivity Software, Precision Medicine, Neuroscience, Clinical Trials, Natural Language Processing, Research, Digital Health, Medical, B2B, Therapeutics, Media and Entertainment, Pharmaceuticals may find it worthwhile to explore potential connections with Marianne Mertens, as their portfolio suggests a familiarity and interest in this area.

Understanding Marianne Mertens’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.